fluticasone propionate

Topical Treatment With Clindamycin for Confluent and Reticulated Papillomatosis in a Pregnant Woman.

Findley Caleb M CM, Neita Buchi B, Dyer Joseph M JM

Confluent and reticulated papillomatosis (CARP) is a rare skin condition that typically shows an effective response to oral minocycline. In this case, we offer support for an alternative therapy with topical clindamycin and glycolic acid for seven weeks, leading to full resolution of CARP in a gravida 2 para 1 woman in her first trimester of pregnancy. Limited evidence exists of topical therapies suitable for use in pregnant individuals without underlying contraindications. Pregnancy limits the use of tetracyclines and retinoid therapies. Therefore, topical clindamycin and glycolic acid offer a low-risk treatment, expanding upon the available options for non-systemic therapies in the management of CARP.

Use of topical treatment among Swedish children with eczema during the first 18 months of life.

Af Klinteberg Maja M, Glas Bo B, Lundberg-Ulfsdotter Richard R, Domellöf Magnus M et al.

Real-world use of topical therapies in children with eczema during the first 18 months of life is insufficiently characterized. Despite guideline recommendations for regular emollients, population-based data on treatment intensity are limited. To quantify topical treatment use at 18 months, proportion reaching recommended emollient dose, and factors associated with repeated dispensing. Data from 18-month-old children (n = 5,275) in the population-based NorthPop Birth Cohort (Västerbotten, Sweden) were analyzed. Atopic dermatitis (AD) was defined using UK Working Party criteria. Eczema severity was assessed with the Patient-Oriented Eczema Measure (POEM). IgE-sensitization was analyzed using ImmunoCAP. Dispensed emollients and topical corticosteroids (TCS) during the first 18 months of life were retrieved from the Swedish Prescribed Drug Register. AD prevalence was 11.6%, higher in boys than girls (12.6% vs 10.5%, p = 0.037). Only 15.1% of children with AD reached recommended emollient dose (≥100 grams/week) (mean 43.5 g/week). Repeated emollient dispensing occurred in 42.5% (≥2 dispensings) and 14.6% had ≥5 dispensings; 60.8% were dispensed TCS. Male sex and IgE-sensitization, but not eczema severity, were associated with repeated dispensing of emollients and TCS. In this population-based cohort, topical treatment for early AD was below guideline recommendations, highlighting the importance of caregiver education and structured follow-up.

Counterfeit hope or bridging the gap? Ethical challenges in patient-sourced topical ruxolitinib for vitiligo.

Nikookam Yasmin Y, Potluru Aparna A, Guckian Jonathan J

Short-Term Efficacy and Safety of Topical Sirolimus Gel in Pediatric Superficial Microcystic Lymphatic Malformations: A Single-Center Interventional Study of 30 Patients.

Xu Weiyang W, Ding Yu Y, Zhao Lei L, Pi Mengqi M et al.

To evaluate the efficacy and safety of 0.2% topical sirolimus gel for pediatric superficial microcystic lymphatic malformations (LMs). This single-center interventional study included 30 pediatric patients (14 males and 16 females; aged 2-15 years) with superficial microcystic lymphatic malformations. All patients received 0.2% topical sirolimus gel twice daily for 12 weeks according to a predefined treatment and follow-up protocol. Clinical efficacy was assessed at baseline and week 12 using clinical examination, standardized photography, symptom scores, and available imaging findings, together with a four-grade physician-assessed response scale. Adverse events were monitored throughout treatment, and blood sirolimus concentrations were measured at weeks 4 and 12. All patients showed lesion reduction, with an overall response rate of 96% (29/30). At week 12, efficacy was graded as IV in 10 patients, III in 11, II in 8, and I in 1. Among patients with pain symptoms, pain scores decreased significantly after treatment (2.88 ± 0.78 vs 1.18 ± 0.88; P < 0.05). In 10 patients with measurable lesions, maximum lesion diameter decreased significantly from 3.22 ± 1.36 cm to 1.89 ± 1.33 cm (P < 0.05). Only mild local adverse effects were observed, and blood sirolimus concentrations remained below 2.0 ng/mL in all patients. Topical sirolimus gel demonstrated favorable efficacy and safety for pediatric superficial microcystic LMs.